Ionis Shares Slide After Phase 3 CARDIO-TTRansform Misses Primary Endpoint
Ionis Pharmaceuticals plunged in pre-market trading after the Phase 3 CARDIO-TTRansform study of eplontersen in transthyretin-mediated amyloid cardiomyopathy failed to meet its primary composite endpoint for cardiovascular mortality and recurrent events through Week 140. The result, disclosed alongside partner AstraZeneca, undercuts a key part of I…